Opendata, web and dolomites

PICSOHF SIGNED

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICSOHF project word cloud

Explore the words cloud of the PICSOHF project. It provides you a very rough idea of what is the project "PICSOHF" about.

expectations    26    feedback    treating    morbidities    patients    changing    treatment    catheter    greatest    picsohf    significantly    temporarily    clinical    hope    people    proof    breakthrough    impoverished    million    threatens    ed    pressure    national    technological    therapy    damaged    burden    right    elevates    improvements    life    met    pattern    profits    prognosis    regain    launch    function    biomarkers    attack    controls    survival    hospitalisations    progressive    commercial    regenerate    medium    patented    heart    recovery    expectancy    strategic    innate    cardiac    percutaneous    frequent    last    healthcare    stop    software    re    scientific    unable    patient    co    despite    sustainability    quality    follow    miracor    therapies    device    regenerative    myocardial    europe    market    intervention    tissue    once    66m    efficacy    partial    cellular    demonstrated    reference    versus    worldwide    changed    proprietary    tested    regeneration    picso    clinically    continuous    acute    treatments    discredited    22    consists    reactivating    solutions    chronic    veins    full    hf    minutes    live   

Project "PICSOHF" data sheet

The following table provides information about the project.

Coordinator
MIRACOR MEDICAL 

Organization address
address: RUE DE BRUXELLES 174, E40 BUSINESS
city: AWANS
postcode: 4340
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIRACOR MEDICAL BE (AWANS) coordinator 50˙000.00

Map

 Project objective

Worldwide 26 million people live with HF (Heart Failure) which is a major burden, not only for the patient, but one that also threatens the sustainability of national healthcare systems. Despite advances in treatment solutions over the last 30 years, improvements have not met the expectations for cardiac recovery and prognosis following heart attack. Current treatments are only partial solutions as they cannot regenerate the damaged heart tissue, and are thus unable to stop the progressive loss of heart function, low short- and medium-term life expectancy, and impoverished quality of life due to co-morbidities and/or frequent and continuous re-hospitalisations. Regenerative concepts, such as cellular therapies to regain cardiac function, once of the greatest hope for heart failure patients, have been recently discredited as they have been unable to show scientific proof of efficacy. Miracor, developed and clinically tested PiCSO, a breakthrough cardiac intervention triggering myocardial regeneration. Our therapy consists of a percutaneous right heart catheter intervention using proprietary software for feedback control that temporarily elevates the pressure in cardiac veins reactivating innate regeneration pathways. We have tested PiCSO in chronic HF patients (8 patients versus 22 controls) and demonstrated that 30 minutes of intervention changed the pattern of regenerative biomarkers in cardiac veins that resulted in significantly improved survival at 10 years follow up. Our patented technology (PiCSOHF ) is changing the market in HF, as no similar device is currently available. Our strategic goal is to become Europe´s leading reference in treating HF. After full technological, clinical and commercial development, PICSOHF profits will increase by €66M within 5 years after commercial launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICSOHF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICSOHF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More